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Abstract
Background:  Although frequently used for tumor surveillance, the sensitivity of
carcinoembryonic antigen (CEA) to detect recurrent colorectal cancer (CRC) is not optimal.
Fluorine 18-fluoro-2-deoxy-glucose-positron emission tomography (18F FDG-PET) scans promise
to improve recurrent CRC detection. We aimed to review PET scans of patients with clinically and/
or radiologically suspicious tumor recurrence but normal CEA.
Methods: A retrospective review of an electronic database of 308 patients with CRC who had
PET scans was performed. Only PET studies of patients with normal CEAs and suspected tumor
recurrence who had pathological verification were selected for further analysis. Thirty-nine
patients met the inclusion criteria.
Results: PET was positive in 26 patients (67%) and normal in 13 (33%). Histopathologic evidence
of tumor recurrence was seen in 27 of the 39 patients (69%). When correlated with histopathology,
PET was true positive in 22 patients, false positive in 4, true negative in 8 and false negative in 5.
Overall, the accuracy of PET was 76.9%, negative predictive value (NPV) was 61.5%, and positive
predictive value (PPV) was 84.6%. PPV value of PET for liver metastases was 88.8% compared to
73.3% for local recurrence. In two patients with confirmed recurrence, CEA became positive 2
months after PET scan indicating earlier detection of disease with PET. The false positive PET
findings were mainly in the bowel and were secondary to acute/chronic inflammation and
granulation tissue. In 3 patients with false negative PET, histopathology was consistent with
mucinous adenocarcinoma.
Conclusion: PET yields high PPV for recurrent CRC, particularly for liver metastases, in spite of
normal CEA levels and should be considered early in the evaluation of patients with suspected
tumor recurrence.
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Background
Colorectal cancer (CRC) is the third most common cause
of cancer in both men and in women in the United States.
The five-year overall survival rates is 64% [1]. Local recur-
rence rate is relatively high despite radical curative surgery
and up to 50% of patients with local recurrence may ben-
efit from surgery.
Early detection and treatment of tumor recurrence is the
only hope for long-term survival. Although carcinoembry-
onic antigen (CEA) is the most frequently used tumor
marker, it has low sensitivity in the early detection of
recurrent colorectal cancer (CRC). Conventional imaging
methods such as Computed Tomography (CT) and Mag-
netic Resonance Imaging (MR) have limited value in dif-
ferentiating post-surgical changes from local tumor
recurrence. Positron Emission Tomography (PET) and,
particularly, Positron Emission Tomography/Computed
Tomography (PET/CT) are widely accepted imaging meth-
ods in the management of a wide variety of cancers,
including CRC. Many studies have demonstrated the
value of PET in the detection of CRC recurrence in patients
with rising CEA in the post-operative period [2-5]. Studies
have also demonstrated the superiority of PET over CT in
the detection of local CRC recurrence as well as metastatic
disease [6-11]. The role of PET in patients with normal
CEA levels, however, is not clear.
In this study, we aimed to analyze the value of FDG-PET
scans in patients with normal CEA levels but clinical or
radiological findings suspicious for tumor recurrence.
Methods
A retrospective review of our electronic database of 308
patients with CRC imaged by PET or PET/CT between Jan-
uary 2003 and December 2005 was performed to select
and analyze PET scan findings of patients who had nor-
mal CEA but clinically and/or radiologically suspicious
findings for tumor recurrence. Only patients with correla-
tive histopathological data were included. The institu-
tional review board allowed an exempt retrospective
review of the cancer PET database, and informed consent
was waived. The normal range for CEA in our clinical lab-
oratory was 0–5.0 ng/mL (chemiluminescent immu-
noassay). Although the CEA levels were available and
normal on all patients at the time of their evaluation for
suspicion of recurrent CRC, initial baseline CEA levels
taken at a time before their initial treatment for their orig-
inally diagnosed CRC were available in only 10 patients
(with initial baseline CEA level within normal range in
seven patients and elevated in three patients).
PET studies were performed on Siemens Biograph 16 PET/
CT and HR plus Siemens CTI PET camera (CTI, Inc,
Knoxville, TN). The patients fasted approximately 6 hours
prior to intravenous injection of 370–555 MBq (10–15
mCi) of Fluorine 18-fluoro-2-deoxy-glucose (18F FDG).
Blood glucose levels were checked prior to the injection of
18F FDG. Studies were performed only when blood glu-
cose levels did not exceed 150 mg/dL. The imaging started
approximately 60 minutes following intravenous injec-
tion of 18F FDG. For the PET/CT camera, first a scout view
was obtained with 30 mAs and 130 kVp followed by a spi-
ral CT scan with 130 mAs, 130 kVp, 5-mm scan width,
and 12-mm feed per rotation without any specific breath-
holding instructions. No IV or oral contrast was given to
the patients for acquisition of the CT images. Imaging area
was from skull base to proximal femora. PET scanning was
performed immediately after acquisition of the CT images
without changing the patient position with 2–4 minutes
per bed acquisition time. PET images were corrected for
attenuation on the basis of the CT data, and iterative
reconstruction algorithms were used for reconstruction.
For the PET only camera, image acquisition time of 10
minutes per bed by using 40% transmission and 60%
emission protocol was used. PET images were corrected
for attenuation on the basis of the transmission image
data, and iterative reconstruction algorithms were used for
reconstruction. PET images were evaluated by two board-
certified nuclear medicine physicians (IS and NCH). PET
scan was considered positive or suspicious when abnor-
mal non-physiologic metabolic activity was identified.
Focal hypermetabolic activity within the liver greater than
adjacent normal liver was considered abnormal. Isometa-
bolic liver lesions (metabolic activity equal to liver) were
only identified with the help of CT in patients with PET/
CT scan. Diffuse mild activity in the bowel was considered
normal physiologic uptake. Quantification of the tumor
metabolic activity was obtained using the Standardized
Uptake Value (SUV) normalized to body weight. Mean ±
SD of maximum-pixel SUV (SUVmax) of the lesions were
calculated. The significance of SUVmax between false posi-
tive and true positive lesions were compared by t-test. A P-
value of less than or equal to 0.05 was considered statisti-
cally significant.
Results
A total of 369 PET studies (PET: 183, from January 2003
to March 2005 and combined PET/CT: 186, from April
2005 to December 2006) in 308 patients with CRC were
reviewed. Only patients with clinical and/or radiological
suspicion of tumor recurrence but normal CEA who have
histopathological evaluation following PET scan were
selected for further analysis. Thirty-nine patients met the
inclusion criteria. The PET studies were performed by PET
scan alone in 27 patients and by combined PET/CT scan
in 12 patients. PET was ordered in these patients because
of suspicious or equivocal lesions on CT in 17, on barium
study in two, or on history and physical exam in 20. The
characteristics of the patients are summarized in Table 1.World Journal of Surgical Oncology 2007, 5:64 http://www.wjso.com/content/5/1/64
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At the time of suspected recurrent CRC, the mean age was
55 with a near-equal gender distribution. The majority of
patients had undergone surgical resection alone with the
remainder having chemotherapy and/or radiotherapy
prior to or following resection. In two patients receiving
chemoradiation, resection of the primary was not under-
taken. Surgical exploration was undertaken within one
month of PET scan in 37 patients and within two months
of PET scan in the other two.
PET scan was considered normal in 13 (33%) and positive
in 26 (67%). At exploration, 27 (69%) patients were
found to have histopathologic evidence of tumor recur-
rence. Of 26 positive PET scans, 22 were true positive and
four were false positive. Eight patients were found to have
true negative PET scans while five were false negative (Fig-
ure 1). In three patients with a false negative PET scan,
tumor was mucinous adenocarcinoma and in the other
two it was moderately differentiated adenocarcinoma.
The overall accuracy of PET was 76.9% with a sensitivity
of 81.4%, specificity of 66.6%, positive predictive value
(PPV) of 84.6%, and negative predictive value (NPV) of
61.5%.
In the 26 patients with positive PET scans, PET detected a
total of 36 lesions, 32 of which were resected. Histopatho-
logical findings in these patients are shown in Table 2.
PPV value of PET was highest for liver metastases (88.8%)
compared to 73.3% for luminal (i.e. anastomotic) recur-
rences. All recurrences and metastases were consistent
with adenocarcinomas with one demonstrating mucinous
features. The exact lesion size was discernable in six
patients and ranged from 10 to 30 mm. In two patients
with pathology proven adenoma with dysplasia in rec-
tum, PET was accepted as true positive for these lesions
due to their pre-malignant nature. Pathology for one
patient (patient number 24 in Table 2) with a false posi-
tive PET scan in the liver (SUVmax of 3.1) showed focal for-
eign body reaction with necrosis, organizing
inflammation, and fibrosis related to previous surgery
(Figure 2). The remaining false positive cases were mainly
in the bowel and were secondary to acute/chronic inflam-
mation and granulation tissue. In patients with a false
positive PET scan, the time interval between last treatment
and PET was 42 months (range:11–96 months). In two
cases with a positive PET scan (patient number 8 and 15
in Table 2), CEA became elevated two months after PET
scan and subsequent pathology demonstrated tumor
recurrence. In one of these two patients, PET showed
increased activity in the liver with central photopenia (Fig-
ure 3) following treatment with Yttrium-90 microspheres.
In one patient (patient number 26 in Table 2) with a false
positive PET scan in the rectum, PET scan also demon-
strated a bone lesion. Follow-up evaluation demonstrated
progression in the bone lesion consistent with metastasis.
In two patients with pathology-proven intra-abdominal
tumor recurrence, PET also demonstrated mediastinal
uptake (patient number 9 and 19 in Table 2). These
lesions remained stable on follow-up PET and CT images.
PET scan and final pathology results of the patients who have  clinically and/or radiologically suspicious tumor recurrence  but normal CEA Figure 1
PET scan and final pathology results of the patients who have 
clinically and/or radiologically suspicious tumor recurrence 
but normal CEA.
Table 1: Patient Characteristics
Characteristics Patients
Mean age [range (year)] 55 (33–91)
Gender
Males 18
Females 21
Mean time interval from initial treatment to PET scan [range (months)] 24 (3–92)
Mean time interval from last treatment to PET scan [range (months)] 25 (3–92)World Journal of Surgical Oncology 2007, 5:64 http://www.wjso.com/content/5/1/64
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In all patients with negative PET and negative pathology
results, follow-up CEA values were available. In six of
these patients, follow-up CEA values were normal (mean
follow-up time 18.8 months, range: 4–41 months). In two
patients, follow-up CEA level increased (mean follow-up
time 3 months, range: 2–6 months).
PET and PET/CT results were evaluated separately. PET
was true positive in 16 patients, false negative in three
patients, and true negative in eight patients. PET/CT was
true positive in six patients, false positive in four patients,
and false negative in two patients. There was no false pos-
itive result with PET and no true negative result with PET/
CT. The accuracy of PET and PET/CT was 88.8% and 50%,
respectively.
Mean ± SD of SUVmax of true positive and false positive
lesions are shown in Table 3. The mean SUVmax in all true
positive lesions tended to be lower than in all false posi-
tive lesions, though this did not reach statistical signifi-
cance (5.51 ± 2.73 vs. 6.75 ± 5.1, p = 0.58). False positive
PET findings associated with bowel showed a trend
towards higher SUVmax compared to true positive lesions,
but this was not statistically significant (8.5 ± 5.5 vs. 6.06
± 3.5, p = 0.45).
Discussion
Approximately 70% of patients with newly diagnosed
CRC are suitable for a curative resection, but up to 50% of
patients recurrence develops usually within two years of
surgery [12-14]. Ten to 50% of local recurrences may be
Table 2: PET and histopathological findings in 26 patients with positive PET scan
No PET/Location SUV Pathology Location of RCRC
1* Rectum 5.8 Tubulovillous adenoma Rectum
2* Rectum 8 MD invasive adeno ca Rectum/P LN
3* Liver 3.4 Colon SD adeno ca met Liver
4* Lung 8.6 Colon adeno ca met Lung
5* Rectum 1.8 MD mucinous adeno ca Rectum
6* Liver 8.2 Colon adeno ca met Liver
7 Liver 6.3 MPD invasive adeno ca Liver
8 Liver 5.5 MD invasive adeno ca Liver
9 Liver 6.9 MPD invasive adeno ca Liver/sigmoid/A LN
Mediastinum 3.8 No biopsy
10 Lung 1.8 Colon IT adeno ca met Lung
Rectum 4.5 Inflammation/granulation
11 Rectum 4.8 MD invasive adeno ca Rectum
AP LN 6.3 No biopsy
12 Multiple liver 6 Colon adeno ca met Liver
13 Liver 3.8 Colon adeno ca met Liver/AP LN/Ovary
AP LN 3.6 Colon adeno ca met
14 Liver 3.1 MD adeno ca met Liver
15 Cecum 1.8 MD adeno ca Cecum/A LN
16 Portal 2.9 Colon adeno ca met Portal/Stomach wall
Upper A 6.1 Colon adeno ca met
17 Sigmoid/Rectum 8.2 Adeno ca Sigmoid/Rectum
18 Rectum 5.4 MD adeno ca Rectum
19 Right colon 11.4 MD adeno ca Right Colon/A LN/Liver
A LN 6.3 Colon adeno ca met
Mediastinium 6.3 No biopsy
20 Rectum 12 MD adeno ca Rectum
21 Rectum 3.2 Tubular adenoma Rectum
22 Rectum 4.3 MD mucinous adeno ca Rectum/Duodenum
Upper A 4 MD mucinous adeno ca
23* Splenic Flexure  6.5 Acute inflammation
24* Liver 3.1 Focal foreign body reaction
A LN 3.3 Acute inflammation
25* Rectum 16.7 Acute inflammation
26* Rectum 6.4 Acute inflammation
Bone 4.1 No biopsy
RCRC: Recurrent CRC, MD: Moderately differentiated, MPD: Moderate to poorly differentiated, SD: Squamoid differentiation, IT: Intestinal type, 
LN: Lymph nodes, A: Abdominal, P: Pelvic, AP: Abdominopelvic, *: Studies done on PET/CT camera.World Journal of Surgical Oncology 2007, 5:64 http://www.wjso.com/content/5/1/64
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suitable for surgical resection [12-20]. In patients with
liver metastasis hepatic resection in properly selected
patients offers up to a 30% chance of cure [21]. Early
detection and prompt treatment of recurrence improves
survival. Although CEA is used frequently in the post-
operative follow-up period, its sensitivity for early detec-
tion of CRC recurrence is less than desirable [22]. Moertel
et al. reported that CEA has a sensitivity of 59% in the
detection of CRC recurrence [23]. CEA is also not specific
for colorectal cancer. A wide variety of non-neoplastic
conditions, such as smoking and liver and gastrointestinal
diseases, may cause elevation in CEA. The use of PET as
part of the diagnostic work-up of patients with rising CEA
is well defined. However, there is a paucity of data con-
cerning its role in patients with suspected CRC recurrence
and normal CEA. We have shown that PET can be reliably
applied in such patients to allow for earlier detection and
management of recurrent CRC.
PET is a functional/metabolic imaging technique which
has been widely used in the diagnosis, staging, and man-
agement of a wide variety of tumors. The most commonly
used PET agent in oncology is 18F FDG, a positron-labeled
non-physiologic analog of glucose. Malignant tumors
avidly accumulate FDG because of accelerated glucose
metabolism and increased rate of glucose transport and
utilization in malignant cells. FDG in the blood is trans-
ported into the cells via glucose transporters and phos-
phorylated to FDG-6-phosphate by hexokinase. This is
thought to occur more readily in tumors due to overex-
pression of the glucose transporters GLUT1 and GLUT3
and higher levels of hexokinase in malignant cells [24].
Because Glucose-6-phosphatase enzyme is low in most of
the tissues and tumors, FDG-6-phosphate cannot be
dephosphorylated to FDG. Therefore, FDG-6-phosphate
cannot cross the cell membrane and is trapped in the cell.
As well, FDG-6-phosphate cannot be utilized in the meta-
bolic steps of glycolysis resulting in accumulation of the
radioactive tracer.
Many studies have demonstrated that FDG-PET has high
sensitivity and specificity in the detection of tumor recur-
rence in patients with rising tumor markers in the absence
of a known source by anatomical imaging methods [2-5].
A meta-analysis determined the overall sensitivity of 97%
and specificity of 76% for FDG PET for detecting recurrent
Table 3: Mean SUVmax ± standard deviation (SD) in true positive and false positive PET lesions based upon location of PET positive 
lesions.
True Positive PET SUVmax (range) False Positive PET SUVmax (range)
Liver 8 5.4 ± 1.8 (3.1–8.2) 1 3.1
Bowel 11 6.06 ± 3.5 (1.8–12) 4 8.5 ± 5.5 (4.5–16.7)
Lymph nodes 3 4.2 ± 1.7 (2–9–6.3) 1 3.3
Lungs 2 5.25 ± 4.87 (1.8–8.7) 0 N/A
Other intra-abdominal 2 5.05 ± 1.48 (4–6.1) 0 N/A
Total 26 5.51 ± 2.73 (1.8–12) 6 6.75 ± 5.1 (3.1–16.7)
N/A – not applicable
Transaxial, sagittal, and coronal PET/CT fusion images in a  patient with prior left lobectomy Figure 2
Transaxial, sagittal, and coronal PET/CT fusion images in a 
patient with prior left lobectomy. PET scan demonstrated a 
focal hypermetabolic activity within the liver at resectin mar-
gin with SUVmaxof 3.1 (arrow). Pathology demonstrated focal 
foreign body reaction with necrosis, organizing inflammation 
and fibrosis secondary to prior surgery.
Transaxial, sagittal, and coronal PET/CT fusion images dem- onstrating a ring-shaped liver lesion (arrow) with increased  metabolic activity (SUVmax:5.5) surrounding a photopenic  center in a patient previously treated with Yittrium-90  microspheres Figure 3
Transaxial, sagittal, and coronal PET/CT fusion images dem-
onstrating a ring-shaped liver lesion (arrow) with increased 
metabolic activity (SUVmax:5.5) surrounding a photopenic 
center in a patient previously treated with Yittrium-90 
microspheres. CEA became positive two months after PET 
and subsequent pathology demonstrated tumor recurrence 
as well as nodal metastasis.World Journal of Surgical Oncology 2007, 5:64 http://www.wjso.com/content/5/1/64
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CRC [25]. Studies have also demonstrated that FDG PET
is more sensitive than CT for the detection of recurrent
CRC [6-11]. PET was found to be superior to CT in the dif-
ferentiation of fibrotic scar tissues from locally recurrent
tumor [26]. The accuracy of PET for locally recurrent dis-
ease was reported as 95% which was superior to pelvic-CT
(65%) [27]. PET is more sensitive than CT in detecting
liver metastases and defining the number of the lobes
involved. Arulapalam et al. reported the sensitivity of PET
and CT as 100% and 45%, respectively, in the detection of
liver metastasis [6]. Similar to CT, MRI also has limita-
tions in the differentiation of fibrotic scar from local
recurrence. Although there is increasing use of dynamic
contrast-enhanced MR, it is not clear yet whether it is
superior to PET in the detection of recurrence. Contrast-
enhanced liver MRI and whole-body FDG-PET were com-
parable in the detection of patients with liver metastases
[28]. PET provided additional information about extrahe-
patic disease. PET is a valuable imaging method to differ-
entiate isolated resectable recurrence from disseminated
metastatic disease to select patients who would benefit
from surgery [29]. Studies have also compared PET and
PET/CT in the detection of CRC recurrence. The sensitiv-
ity, specificity and overall accuracy of PET were 80%, 69%,
and 75%, respectively, compared with 89%, 92%, and
90%, respectively, for PET/CT [30]. Another study demon-
strated superiority of PET/CT over PET in differentiating
malignant from benign lesions and physiologic activities
[31]. The most common cause for false-positive interpre-
tation of PET findings was physiologic FDG uptake in pel-
vic organs.
In our study, histopathological analysis following PET
scan demonstrated tumor recurrence or metastasis in 27
of 39 patients who have normal CEA but clinically and/or
radiologically suspicious tumor recurrence. Twelve
patients were tumor free. PET was true positive in 22
patients and true negative in eight patients. The accuracy
of PET was 76.9%. Our results demonstrated that PET was
most accurate for liver metastases with a positive predic-
tive value 88.8%. For local recurrence, PET had PPV of
73.3%. PET was false negative in five patients. In three of
these patients pathology was consistent with mucinous
carcinoma with signet cells. Consistent with our findings,
it has been reported that the sensitivity of FDG-PET imag-
ing for detection of mucinous carcinoma is significantly
lower than in nonmucinous carcinoma (58% and 92%,
respectively) [8]. PET was false positive in four patients.
False positive PET lesions were mainly in the bowel and
were secondary to infectious or inflammatory/granuloma-
tous processes. False-positive findings with FDG-PET in
colorectal region are not uncommon [32]. Increased FDG
uptake is observed at recent incision and biopsy sites,
around drainage tubes and catheters, and at colostomy
sites, as well as in association with colitis, abscesses, fistu-
las, diverticulitis, and in some benign adenomas. This is
because of increased glucose use in activated macro-
phages, neutrophils, and fibroblasts within infectious,
inflammatory, and granulomatous tissues. Normal FDG
uptake in the gastrointestinal tract may also cause diffi-
culty to differentiate normal physiologic uptake from
recurrent tumor.
There are many factors affecting the serum concentration
of CEA, including tumor location, proximity to large ves-
sels, degree of de-differentiation, access to portal circula-
tion, tumor distribution, and tumor burden. Previously
Moertel et al reported the inadequacy of CEA for early
detection of tumor recurrence [23]. Only 25% of the
patients had abnormal CEA levels although most patients
had symptoms of recurrence for several months in their
study. In two of our patients, CEA became positive 2
months after PET scan, suggesting that PET can show
tumor recurrence earlier than CEA elevation. In our study,
the lesion size was measured in focal solitary liver metas-
tases in six patients. The tumor size ranged from 10 mm
to 30 mm. However, our data is not sufficient to find the
smallest tumor volume where PET can be positive while
CEA negative. There are also many other factors in addi-
tion to tumor size affecting CEA level. However, we
assume that given directly imaging the tumor and high
glucose metabolism in tumor tissue, as well as current
high-resolution PET/CT cameras, it is expected that FDG-
PET may detect tumor recurrence before significant
increase in CEA level.
Although PET facilitates the evaluation of metabolic char-
acteristics of tumors, it is limited in its ability to visualize
anatomical structures. A PET/CT camera is the combina-
tion of PET and CT cameras which allows more accurate
registration of metabolic findings in tumor with anatom-
ical findings, adding further information to the diagnosis
and staging of tumors. In PET/CT cameras, CT is also used
for attenuation correction of PET images which signifi-
cantly reduces imaging time. In our study, the accuracy of
PET/CT was found to be lower than PET alone. However,
given the smaller number of exams performed by PET/CT
than by PET alone, this determination of accuracy may
not reliably reflect the actual accuracy of PET/CT versus
PET alone.
Our study had several potential limitations. The first
potential limitation was our small sample size which may
have limited the robustness of our study in terms of statis-
tics. The second potential limitation was the retrospective
nature of our study. Because of its retrospective nature, we
were unable to obtain baseline clinical and laboratory
data in some of the patients. The third potential limitation
was the pooled nature of the PET and PET/CT data, given
that different attenuation correction algorithms were usedWorld Journal of Surgical Oncology 2007, 5:64 http://www.wjso.com/content/5/1/64
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in these two imaging methods. However, this issue would
be of more concern had we compared PET SUVmax to
PET/CT SUVmax in the same given patient. In defense of
this third potential limitation, there is recently published
study pooling PET and PET/CT SUV results [33]. The
fourth potential limitation was our inability to use oral
contrast for the combined PET/CT studies, since some
data is available which demonstrates that low density oral
contrast administration during combined PET/CT studies
further increases accuracy.
Conclusion
Although PET is commonly used to localize tumor recur-
rence in cases with elevated CEA, our results indicate that
PET is also valuable to detect tumor recurrence in selected
cases who have normal CEA but clinically and/or radio-
logically suspicious tumor recurrence. The PPV of PET is
high, particularly in detecting liver metastases. While PET
may not be practical for routine surveillance for all
patients with CRC, it should be utilized in select cases
where CEA is not reliable, such as tumors known to not
secrete CEA. PET should also be utilized at the first sign of
suspected recurrence to determine the extent of disease.
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